TheraRadar
← Back
Data updated: Mar 29, 2026

WUXI

ImmunologyMetabolicCardiovascular
Generics

WUXI is a generic drug manufacturer focused on Immunology, Metabolic, Cardiovascular.

2024
Since
1
Drugs
-
Trials
56
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

MYCOPHENOLATE MOFETIL 2026-02-23
Labeling
MYCOPHENOLATE MOFETIL 2026-01-14
Labeling
MYCOPHENOLATE MOFETIL 2026-01-14
Labeling
MYCOPHENOLATE MOFETIL 2025-02-12
Labeling
MYCOPHENOLATE MOFETIL 2025-02-12
Labeling
MYCOPHENOLATE MOFETIL 2025-02-12
Labeling
MYCOPHENOLATE MOFETIL 2025-02-12
Labeling
MYCOPHENOLATE MOFETIL 2025-02-12
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Immunology 22%
0 drugs Phase 3: 1
Metabolic 22%
0 drugs Phase 3: 1
Cardiovascular 22%
0 drugs Phase 3: 1
Respiratory 22%
0 drugs Phase 3: 1
Oncology 11%
0 drugs Phase 1: 2

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Novartis big-pharma
Oncology, Cardiovascular, Immunology, Respiratory
AstraZeneca big-pharma
Oncology, Respiratory, Cardiovascular, Metabolic, Immunology
Merck big-pharma
Oncology, Cardiovascular, Immunology, Metabolic
Boehringer Ingelheim big-pharma
Metabolic, Oncology, Respiratory, Immunology, Cardiovascular
Johnson & Johnson big-pharma
Oncology, Immunology, Cardiovascular, Metabolic